{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-26-000038","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2026-07-23T20:29:00+00:00","discovered_at":"2026-07-23T20:30:00.221409+00:00","generated_at":"2026-07-23T20:30:22.049110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edwards Q2 sales up 13.6% to $1.74B; raises full-year sales and TAVR guidance","bullets":["Q2 sales $1.74B (+13.6% YoY); adjusted EPS $0.78; gross margin 77.5%.","TAVR sales $1.26B (+11.3% YoY); TMTT sales $195.9M (+47.3% YoY); Surgical $284M (+6.5% YoY).","Raised FY constant currency sales growth guidance to 10-11% (from 9-11%); TAVR growth to 8-9% (from 7-9%).","Reaffirmed adjusted EPS guidance $2.95-$3.05; Q3 guidance: sales $1.63-$1.71B, adj EPS $0.71-$0.77.","Cash $2.9B, debt $600M; $1.5B remaining share repurchase authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-26-000038","json":"https://secwatch.observer/filing/0001099800-26-000038.json","markdown":"https://secwatch.observer/filing/0001099800-26-000038.md","text":"https://secwatch.observer/filing/0001099800-26-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/0001099800-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T20:30:22.049110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}